Chemotherapy for ovarian cancer in Israel — get 3 top clinic matches with costs

Israel provides advanced ovarian cancer chemotherapy through Hyperthermic Intraperitoneal Chemotherapy (HIPEC), targeted PARP inhibitors, and immunotherapy. Leading centers like Assuta and Sourasky (Ichilov) utilize genetic profiling to tailor dose-dense regimens and antibody-drug conjugates, achieving high survival rates for complex cases within JCI-accredited facilities.

• HIPEC treatment: Heated drugs circulate in the abdomen during surgery to kill microscopic cells.
• Targeted therapy: Maintenance protocols involve PARP inhibitors and folate receptor-alpha agents like Elahere.
• Immunotherapy access: Advanced medications like Keytruda boost immune responses against specific cancer markers.
• Neoadjuvant protocols: Specialized infusions shrink tumors before debulking surgery to improve surgical outcomes.

Bookimed Expert Insight: Israeli oncology centers demonstrate high expertise by integrating clinical trials directly into treatment plans. Dr. Irina Stepfansky at Sourasky serves as a primary investigator for Phase I-III trials. This gives patients access to emerging protocols like RNA-based nanodrugs often unavailable in standard hospitals.

Patient Consensus: Patients often emphasize the necessity of BRCA and HRD genetic testing to unlock maintenance therapies. Many recommend using cooling mitts during infusions to manage side effects and maintain quality of life.

Targeted therapies for ovarian cancer in Israel prioritize personalized protocols based on molecular profiling. Key treatments include PARP inhibitors for BRCA mutations, angiogenesis inhibitors like Bevacizumab, and advanced antibody-drug conjugates such as Mirvetuximab soravtansine for folate receptor alpha-positive cases within JCI-accredited centers in Tel Aviv.

• PARP inhibitors: Use Olaparib and Niraparib for maintenance in HRD-positive tumors.
• Antibody-drug conjugates: Mirvetuximab soravtansine (Elahere) targets platinum-resistant, folate receptor alpha-positive cases.
• Combination protocols: Doctors pair Pembrolizumab (Keytruda) with specialized niraparib cycles for improved outcomes.
• Molecular profiling: Specialists use FoundationOne CDx to identify specific KRAS or HER2 mutations.

Bookimed Expert Insight: Israel offers exceptionally fast access to phase I-III clinical trials for B7-H4 targeted drugs. Dr. Irina Stepfansky at Sourasky Medical Center (Ichilov) coordinates these trials. This allows patients to access therapies like Avutometinib years before they reach standard global markets.

Patient Consensus: Patients emphasize that biomarker testing for FRα and HRD status is essential before starting. Many highlight the availability of compassionate use programs for new drugs not yet on national lists.

Israel provides specialized molecular diagnostics for ovarian cancer, using genetic profiling to identify BRCA1/2 mutations and FRα expression. JCI-accredited centers like Assuta and Sourasky perform comprehensive tumor sequencing. These diagnostics guide personalized protocols including targeted therapy, immunotherapy, and enrollment in advanced clinical trials.

• Molecular markers: Testing identifies BRCA1/2 and Folate Receptor Alpha (FRα) status.
• Leading facilities: Assuta Medical Center performs 685,000 diagnostic procedures annually near Tel Aviv.
• Expert oversight: Specialists like Dr. Irina Stepfansky manage advanced phase I-III clinical trials.
• Diagnostic timeline: Complex genomic profiling requires more than a 1–2 day laboratory turnaround.

Bookimed Expert Insight: While research into liquid biopsies and cell-free DNA screening is high in Israel, these tools are often part of clinical trials rather than standard care. Clinics like Assuta pair JCI-accredited diagnostic accuracy with high surgical volume, performing 92,000 operations annually, which ensures biological samples are handled by high-capacity, experienced pathology teams.

Patient Consensus: Patients emphasize verifying Folate Receptor Alpha status before beginning treatment, as this specific diagnostic result determines eligibility for many modern targeted therapies. They also note that molecular testing is time-intensive, so international travelers should plan for a longer diagnostic window.

Immunotherapy is an active treatment option for ovarian cancer in Israel, primarily used for advanced or recurrent cases. Israeli oncologists utilize FDA-approved drugs like Pembrolizumab and Dostarlimab for patients with specific genetic markers, often integrating them into personalized protocols based on molecular testing.

• Approved therapies: Clinics prescribe Pembrolizumab (Keytruda) for microsatellite instability-high or mismatch repair deficient tumors.
• Specialized expertise: Experts like Dr. Irina Stepfansky manage advanced protocols for gynecologic oncology cases.
• Clinical trials: Patients access innovative treatments including tumor-infiltrating lymphocyte therapy and RNA-based nanodrugs.
• Advanced diagnostics: Molecular tests like FoundationOne CDx identify unique tumor profiles to determine eligibility.

Bookimed Expert Insight: Israeli oncology centers like Assuta and Sourasky prioritize targeted therapies over pure immunotherapy for initial treatment. Data shows that doctors often recommend testing for Homologous Recombination Deficiency before immunotherapy. This approach identifies patients who benefit more from PARP inhibitors, ensuring more effective first-line outcomes.

Patient Consensus: Patients emphasize that immunotherapy is rarely a standalone or first-line choice for this diagnosis. Success often depends on participating in clinical trials for platinum-resistant cases where standard chemotherapy has failed.

The standard first-line chemotherapy for ovarian cancer is a combination of carboplatin and paclitaxel. This doublet regimen typically involves 6 cycles administered intravenously every 3 weeks. Surgeons often provide this adjuvant treatment after debulking to eliminate residual cancer cells.

• Core regimen: Carboplatin and paclitaxel (Taxol) form the primary platinum-taxane doublet therapy.
• Treatment duration: Most protocols require 6 cycles over 5 months for maximum efficacy.
• Delivery methods: Options include standard intravenous infusion or localized intraperitoneal therapy for advanced stages.
• Maintenance therapy: Doctors may add PARP inhibitors like Lynparza or Bevacizumab to prevent recurrence.

Bookimed Expert Insight: Israeli oncology centers like Sourasky Medical Center utilize advanced sequencing. Dr. Irina Stepfansky emphasizes neoadjuvant chemotherapy, where 3 cycles precede surgery. This specific timing often shrinks widespread tumors, making surgical debulking more successful and improving overall survival rates.

Patient Consensus: Completing all six cycles is vital as clinical data confirms its effectiveness for long-term remission. Patients often suggest asking about BRCA mutation testing to qualify for targeted maintenance therapies like PARP inhibitors.

Treatment goals for recurrent ovarian cancer focus on extending survival, suppressing disease progression, and maximizing quality of life. Since the condition is managed as a chronic illness, specialists aim to achieve further remissions and provide extended time off treatment while managing symptoms effectively.

• Disease stabilization: Using systemic chemotherapy to control growth and achieve no evidence of disease.
• Survival extension: Employing targeted therapies or PARP inhibitors to prolong overall lifespan significantly.
• Symptom management: Prioritizing palliative care to ensure daily comfort and high functional levels.
• Maintenance strategy: Utilizing angiogenesis inhibitors to delay future flare-ups and maintain responsiveness.

Bookimed Expert Insight: Israeli oncology centers like Assuta or Sourasky often emphasize specialized diagnostic precision, such as RUTH mammography or advanced PET-CT. This allows experts like Dr. Irina Stepfansky to tailor clinical trials specifically for platinum-resistant cases. Selecting a JCI-accredited facility ensures these advanced protocols meet international safety standards.

Patient Consensus: Many patients find that treating recurrence like a manageable chronic condition reduces emotional stress. They highlight the importance of proactive CA-125 monitoring to catch changes early before symptoms appear.

Chemotherapy for ovarian cancer typically causes temporary fatigue, hair loss, and peripheral neuropathy. While attacking malignant cells, platinum-based agents and taxanes affect healthy tissues. Israeli oncologists mitigate these impacts through personalized dosing and supportive medications to maintain patient quality of life during cycles.

• Physical exhaustion: Severe fatigue can leave patients bedridden for 3 to 5 days post-session.
• Neurological changes: Taxanes may cause numbness, tingling, or buzzing in fingers and toes.
• Gastrointestinal distress: Treatment often causes severe constipation, nausea, and bitter taste perceptions.
• Immunological risk: Low white blood cell counts significantly increase the risk of systemic infections.

Bookimed Expert Insight: While many focus on hair loss, our data shows patients often overlook sensory side effects. For instance, cisplatin-based regimens commonly used in JCI-accredited centers like Assuta carry higher risks for tinnitus. Modern Israeli protocols now incorporate scalp cooling and specialized hydration to reduce specific side effects like chemical sweat odors or localized skin peeling.

Patient Consensus: Patients frequently report that hair loss occurs rapidly, often within 6 days of the first dose. Many recommend keeping a daily symptom journal to track bowel habits and neurological changes for better oncologist consultations.